title: Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis.
abstract: Plasminogen activator inhibitor type 1 (PAI-1) is an inhibitor of plasmin production. Plasmin can directly or indirectly to degrade cartilage and bone matrix. The PAI-1 HindIII polymorphism has been associated with high PAI-1 plasma levels in myocardial infarction patients and control populations. Furthermore, it has been associated with the angiographic extent of coronary artery disease, but their involvement in other diseases is still uncertain. Here, we assessed the relationship between PAI-1 HindIII polymorphism and PAI-1 plasma levels in rheumatoid arthritis (RA). One hundred and twenty-five RA patients and 132 control subjects (CS) were included. Genotypes were identified by the polymerase chain reaction-restriction fragment length polymorphism technique and PAI-1 plasma levels were quantified using an ELISA kit. Not significant differences in genotype and allele frequencies between both studied groups were observed (P > 0.05). RA patients showed lower PAI-1 plasma levels (18.92 +/- 12.94 ng/ml) than CS (23.68 +/- 23.38 ng/ml), without significant difference (P = 0.299). However, in RA patients the C/G genotype carriers showed higher PAI-1 plasma levels (23.00 +/- 13.81 ng/ml) with respect to C/C (16.77 +/- 11.97 ng/ml) and G/G (10.47 +/- 7.07 ng/ml) genotype carriers (P = 0.036). The PAI-1 HindIII polymorphism was not associated with RA susceptibility. However, the C/G genotype is associated with high PAI-1 plasma levels in RA patients.
authors.affiliation: Departamento de Biología Molecular y Genómica, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
authors.forename: Norma
authors.initials: N
authors.lastname: Torres-Carrillo
authors.forename: Nora Magdalena
authors.initials: NM
authors.lastname: Torres-Carrillo
authors.forename: Gloria Esther
authors.initials: GE
authors.lastname: Martínez-Bonilla
authors.forename: Mónica
authors.initials: M
authors.lastname: Vázquez-Del Mercado
authors.forename: Claudia Azucena
authors.initials: CA
authors.lastname: Palafox-Sánchez
authors.forename: Edith
authors.initials: E
authors.lastname: Oregón-Romero
authors.forename: Ana Guilaisne
authors.initials: AG
authors.lastname: Bernard-Medina
authors.forename: Héctor
authors.initials: H
authors.lastname: Rangel-Villalobos
authors.forename: José Francisco
authors.initials: JF
authors.lastname: Muñoz-Valle
mesh_terms: D001172:Arthritis, Rheumatoid / Q000473:pathology*; D015247:Deoxyribonuclease HindIII / Q000378:metabolism; D004198:Disease Susceptibility; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005787:Gene Frequency; D006801:Humans; D010949:Plasma / Q000737:chemistry; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood* / Q000235:genetics*; D016133:Polymerase Chain Reaction / Q000379:methods; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length
chemical_list: D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D015247:Deoxyribonuclease HindIII